Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis Olofsson SO; Boren JJ Intern Med 2005[Nov]; 258 (5): 395-410Apolipoprotein (apo) B exists in two forms apoB100 and apoB48. ApoB100 is present on very low-density lipoproteins (VLDL), intermediate density lipoproteins (IDL) and LDL. ApoB100 assembles VLDL particles in the liver. This process starts by the formation of a pre-VLDL, which is retained in the cell unless converted to the triglyceride-poor VLDL2. VLDL2 is secreted or converted to VLDL1 by a bulk lipidation in the Golgi apparatus. ApoB100 has a central role in the development of atherosclerosis. Two proteoglycan-binding sequences in apoB100 have been identified, which are important for retaining the lipoprotein in the intima of the artery. Retention is essential for the development of the atherosclerotic lesion.|Apolipoprotein B-100[MESH]|Apolipoprotein B-48[MESH]|Apolipoproteins B/chemistry/*metabolism[MESH]|Arteriosclerosis/*etiology/metabolism[MESH]|Glycosaminoglycans/metabolism[MESH]|Humans[MESH]|Hyperlipidemias/metabolism/prevention & control[MESH]|Lipoproteins, VLDL/chemistry/metabolism[MESH]|Models, Biological[MESH]|Proteoglycans/metabolism[MESH]|Risk Factors[MESH]|Triglycerides/metabolism[MESH] |
